Breaking Down AbbVie: 7 Analysts Share Their Views
Portfolio Pulse from Benzinga Insights
AbbVie (NYSE:ABBV) was analyzed by 7 analysts, showing a mix of bullish to bearish sentiments. The average 12-month price target is $171.57, with a high of $196.00 and a low of $150.00, slightly down from the previous $173.40. Analysts from Barclays, HSBC, Goldman Sachs, Raymond James, Deutsche Bank, and Morgan Stanley have updated their ratings and price targets. AbbVie's financial performance shows a revenue decline of -5.97% for the quarter ending September 30, 2023, but strong net margin and ROE. The company's debt-to-equity ratio is high at 5.02, indicating potential financial challenges.
January 23, 2024 | 2:01 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
AbbVie received mixed analyst ratings with a slight decrease in the average price target. The company's financials indicate a revenue decline but strong profitability metrics. High debt levels may pose risks.
The mixed analyst ratings and slight decrease in the average price target suggest uncertainty, which could lead to a neutral short-term impact on ABBV's stock price. The strong net margin and ROE are positive, but the high debt-to-equity ratio and revenue decline may concern investors. The overall impact is neutral due to these offsetting factors.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100